NCT07220577

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).

Detailed description

This is a randomized, placebo-controlled, parallel-group, non-confirmatory, investigator and participant blinded study in adult participants with moderate to severe AD.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	GIA632	Active treatment arm
OTHER	Placebo	Placebo treatment arm

Timeline

• Start date: 2025-11-10
• Primary completion: 2027-05-17
• Completion: 2027-09-06
• First posted: 2025-10-24
• Last updated: 2026-04-06

Locations

28 sites across 9 countries: United States, Bulgaria, Canada, Czechia, France, Germany, Malaysia, Poland, Singapore

Regulatory

• FDA-regulated drug study